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Patient # Age/sex Involvement Pretreatment Status at alloSCT Conditioning Donor Outcome
1 64/m Skin ALL-like, HD-Mtx CR2 Flu-Bu-Cy-ATG MMUD 8/10 Chronic GVHD, alive in CR, 441 mo
2 67/m Skin, BM ALL-like, Gemcitabine Refractory Flu-Bu-Cy-ATG MMUD 9/10 Dead (REL 71 mo)
3 69/m Skin, BM AML-like Refractory Flu-Treosulfan-ATG MUD 10/10 Alive in CR 71 mo
4 55/f Skin ALL-like CR1 Flu-Bu-Cy-ATG MUD 10/10 Alive in CR 51 mo
Poster Session I S233Six consecutive patients with BPDC have been treated at our insti-
tution between 2004 and 2008. All patients responded to acute leu-
kemia-like induction therapy. Whereas two patients were ineligible
for alloSCT due to comorbidity and experienced rapid relapse, 4 pa-
tients proceeded to RIC alloSCT as part of first-line (n5 1) or sal-
vage treatment (n5 3) (Table). Median age was 66 (55-69) years.
Two patients had active disease at the time of alloSCT. Condition-
ing was based on submyeloablative doses of busulfan or treosulfan
with fludarabine and ATG, followed by transplantation of unmanip-
ulated peripheral blood stem cell grafts obtained from matched or
mismatched unrelated donors. Three patients live progression-free
44, 7 and 5months post alloSCT, one patient relapsed 7months after
SCT and died soon thereafter.
We conclude that RIC SCT from unrelated donors is feasible in
elderly patients with BPDC and might provide curative potential
in this otherwise incurable disease. Prospective analyses of RIC al-
loSCT in BPDC are warranted.202
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Introduction: Age remains probably the most important prognos-
tic factor in acute lymphoblastic leukemia (ALL). Adults with ALL
have poor outcome with chemotherapy when compared to chil-
dren; as age increases overall survival (OS) continuously declines.
Elderly ALL (EALL) patients (pts) have the worst outcome with
chemotherapy. Despite good initial response to induction chemo-
therapy, relapse rate (RR) is high and most pts will succumb to
their disease. Few studies have addressed the outcome of EALL
with chemotherapy.
Patients and Methods: Retrospective analysis of 32 EALL pts
treated with chemotherapy at the L/BMT program of BC, Canada
between 1989-2008. EALL was defined by age $60 years. Cytoge-
netics was available on 28(87.5%) pts. All pts received a consistent in-
duction/consolidation and maintenance chemotherapy as per our
modified ALL89-01 protocol. Complete remission (CR), Event
free survival (EFS) and OS were analyzed.
Results:Betwen1989-2008, 32 pts (8.7% of adult ALL) were EALL,
median age 66.0(60.1-76.1) years, 50% males. Median wbc count
was 7.4(0.8-43) x109/L. 7/32(28%) were Ph+. Only one pt had
CNS involvement. All pts received a consistent induction with dau-
norubicin, vincristine and prednisone. 27/32(84.4%) achieved CR.
18/27(66.7%) of pts. who achieved CR received phase II induction
consisting of cyclophosphamide, cytarabine, and mercaptopurine.
Consolidation chemotherapy was given in 17/27 (62.9%), in 15/
17(88.2%) consisted of 1-2 cycle of cytarabine and tenoposide. 6
pts also received modified intensification with vincristine, daunoru-
bicin, cyclophosphamide. 4 pts received tyrosine kinase inhibitor
(TKI) with consolidation. 2 pts received other chemotherapy. Main-
tenance with methotrexate and mercaptopurine were given in 20 pts
which include 4 pts who did not receive consolidation. 23/27(85.2%)
pts who achieved CR had relapse. Median time to relapse from diag-
nosis is 240(112-1317) days. Median EFS and OS are 313(0-1317)
and 489(38-1770) days, respectively. Cause of death was disease pro-
gression in 25/27 (92.6%). 6/7(85%) of Ph+ pts received combina-tion chemotherapy with TKI. 3-year OS for the whole group was
26%, 36% for Ph+ pts and 23% for Ph- ALL.
Conclusions: EALL have poor outcome with chemotherapy. De-
spite the excellent CR rate with chemotherapy (84.4%), RR remains
high (85.2%) and most patients (96.2%) die secondary to DP. In the
TKI’s era, EALL with Ph+ disease relatively fair better than Ph-
EALL.
3-year disease free survival and over all survival
All Patient Ph1 group Ph- group P valueNumber 32 7 25
3-year DFS 15% 0% 19% 0.20
3-year-OS 26% 36% 23% 0.81LYMPHOMA/MULTIPLE MYELOMA
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AND RELAPSING MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP
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Allogeneic SCTwithmyeloablative conditioning is potentially cu-
rative therapy for multiple myeloma (MM), but is associated with ex-
cessively high rates of non-relapse mortality (NRM). Reduced-
intensity conditioning (RIC) allows reduction of NRM but relapse
rate is increased. The role and timing of allogeneic SCT during
the disease course are controversial. There is only limited data on
the long-term outcome of RIC in the relapsing/refractory setting.
We retrospective analyzed SCT outcomes in 50 patients (pts) given
RIC for relapsing/refractory MM, between the years 2000-2004,
from related (n5 27) or unrelated (n5 23) donors. The median
age was 53 years (32-64). This was a relatively heavily pretreated
group, amedian of 3 years from diagnosis (0.5-14 years). Forty-seven
pts failed one (n5 31) or two (n5 16) prior autologous SCT. Thirty
pts were in PR (n5 26) or CR (n5 4) at the time of SCT and 20 pts
had stable or progressive disease. RIC consisted of fludarabine and
melphalan (100-140 mg/m2). Disease response was assessed at day
+100; 23 pts achieved CR; 17 PR, 7 died and 3 have already pro-
gressed by day +100. With a median follow-up of 6.4 years (range,
5-7.9 years), 16 pts are alive and 34 have died; 13 had NRM (cumu-
lative incidence 26%) and 21 died of relapse. The median survival is
2.3 years and the estimated 7-year overall and progression-free sur-
vival (PFS) rates were 34% (95 C.I. 21-47%) and 26% (95 C.I. 14-
38%), respectively. The PFS curve showed an apparent plateau after
3 years, with no later relapses, suggesting a potential cure. In multi-
variate analysis, adverse prognostic factors for survival included SCT
not in remission, long duration of disease and SCT from a female do-
nor to a male recipient. Related and unrelated donor SCT had a sim-
ilar outcome. The 7 year PFS in 19 pts with none of these adverse
factors was 47%. Chronic GVHD and achievement of CR after
SCTwere associated with improved outcome. In conclusion, alloge-
neic SCT can result in long-term PFS in a subset of MM pts failing
prior therapy and should be considered early after failure and prefer-
ably after achieving a response with salvage therapy. The treatment
goal is to achieve a CR as this is associated with better outcome.
